GlassScriptPrepare for your visit
Peter Mancini
Cardiovascular Disease · Dearborn, MI · NPI 1831129477
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$7,174.71
in general payments reported to CMS, 2019-2025 · $976 in 2025
The $976 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Who reported paying
General payments only, top 6 by amount.
- Novartis Pharmaceuticals Corporation $1,020.43
- E.R. Squibb & Sons, L.L.C. $741.82
- Boehringer Ingelheim Pharmaceuticals, INC. $701.43
- Merck Sharp & Dohme LLC $688.95
- Janssen Pharmaceuticals, INC $665.51
- Sanofi-Aventis U.S. LLC $461.92
Drugs and devices associated with these payments
Verquvo Jardiance Leqvio Camzyos Eliquis Xarelto Wegovy Wainua Kerendia Lifevest Multaq Arcalyst
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Peter Mancini listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/128600/peter-mancini